Spectrumdna Stock Performance
| SPXA Stock | USD 0.01 0.00 0.00% |
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and SpectrumDNA are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days SpectrumDNA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, SpectrumDNA is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
SpectrumDNA | Build AI portfolio with SpectrumDNA Stock |
SpectrumDNA Relative Risk vs. Return Landscape
If you would invest 0.98 in SpectrumDNA on October 31, 2025 and sell it today you would earn a total of 0.00 from holding SpectrumDNA or generate 0.0% return on investment over 90 days. SpectrumDNA is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than SpectrumDNA, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
SpectrumDNA Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of SpectrumDNA for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for SpectrumDNA can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| SpectrumDNA generated a negative expected return over the last 90 days | |
| SpectrumDNA has some characteristics of a very speculative penny stock | |
| SpectrumDNA has high likelihood to experience some financial distress in the next 2 years | |
| SpectrumDNA currently holds 15.83 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. SpectrumDNA has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about SpectrumDNA's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 141.25 K. Net Loss for the year was (1.97 M) with profit before overhead, payroll, taxes, and interest of 137.17 K. | |
| SpectrumDNA currently holds about 4.22 K in cash with (1.12 M) of positive cash flow from operations. |
SpectrumDNA Fundamentals Growth
SpectrumDNA Stock prices reflect investors' perceptions of the future prospects and financial health of SpectrumDNA, and SpectrumDNA fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SpectrumDNA Stock performance.
| Return On Equity | -13.03 | |||
| Return On Asset | -3.92 | |||
| Operating Margin | (9.97) % | |||
| Current Valuation | 237.12 K | |||
| Shares Outstanding | 59.28 M | |||
| Price To Earning | (0.07) X | |||
| Price To Sales | 4.85 X | |||
| Revenue | 141.25 K | |||
| EBITDA | (1.41 M) | |||
| Cash And Equivalents | 4.22 K | |||
| Total Debt | 15.83 K | |||
| Debt To Equity | 0.04 % | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (1.12 M) | |||
| Earnings Per Share | (0.04) X | |||
| Total Asset | 534.25 K | |||
| Retained Earnings | (9.05 M) | |||
| Current Asset | 4 K | |||
| Current Liabilities | 87 K | |||
About SpectrumDNA Performance
By analyzing SpectrumDNA's fundamental ratios, stakeholders can gain valuable insights into SpectrumDNA's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if SpectrumDNA has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if SpectrumDNA has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Spectrum DNA, Inc. operates a social media studio that creates digital networked applications, which are engines of engagement primarily for media outlets and brand advertisers. The company was founded in 2006 and is based in Park City, Utah. Spectrumdna operates under Internet Information Providers classification in the United States and is traded on OTC Exchange. It employs 8 people.Things to note about SpectrumDNA performance evaluation
Checking the ongoing alerts about SpectrumDNA for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for SpectrumDNA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| SpectrumDNA generated a negative expected return over the last 90 days | |
| SpectrumDNA has some characteristics of a very speculative penny stock | |
| SpectrumDNA has high likelihood to experience some financial distress in the next 2 years | |
| SpectrumDNA currently holds 15.83 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. SpectrumDNA has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about SpectrumDNA's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 141.25 K. Net Loss for the year was (1.97 M) with profit before overhead, payroll, taxes, and interest of 137.17 K. | |
| SpectrumDNA currently holds about 4.22 K in cash with (1.12 M) of positive cash flow from operations. |
- Analyzing SpectrumDNA's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether SpectrumDNA's stock is overvalued or undervalued compared to its peers.
- Examining SpectrumDNA's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating SpectrumDNA's management team can have a significant impact on its success or failure. Reviewing the track record and experience of SpectrumDNA's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of SpectrumDNA's stock. These opinions can provide insight into SpectrumDNA's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for SpectrumDNA Stock analysis
When running SpectrumDNA's price analysis, check to measure SpectrumDNA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpectrumDNA is operating at the current time. Most of SpectrumDNA's value examination focuses on studying past and present price action to predict the probability of SpectrumDNA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpectrumDNA's price. Additionally, you may evaluate how the addition of SpectrumDNA to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |